AskGene Pharma, Inc. (“AskGene”) is a U.S. based biotechnology firm located in Camarillo, California. AskGene’s mission is to develop and bring our patients “me-too” and biosuperior molecules with validated targets. Currently, we have monoclonal antibodies, bi-specific antibodies and fusion proteins in our development pipeline.
AskGene was founded by a team of highly accomplished scientists from leading biotech organizations and financially supported by Jiangsu Aosaikang pharmaceuticals (China A share market 002755). Since then, AskGene has leveraged its scientific strengths and technical infrastructure to rapidly develop therapeutic molecules (monoclonal antibodies and fusion proteins), with its first IND approved within 7 months from its submission to CFDA and entering phase 1 clinical trial in 2017. Currently, AskGene has multiple ongoing clinical trials in USA and China.
AskGene is equipped with most advanced R&D facilities with above 10000 sq.ft R&D space in southern California and a manufacturing pilot plant in Nanjing ready to launch in 2019 Q3. Development is carried out with high standards of safety, efficacy and efficiency. We require our employees to have professional skills and in-depth knowledge about commercialization of recombinant therapeutics.